Gates Foundation joins $26M round for developer of flu drug

11/12/2012 | Mass High Tech (Boston) · Xconomy

Visterra secured an additional $13 million in a Series A funding round from existing and new investors, bringing the total raised to $26 million. The biotech startup will use the money to advance VIS410, an antibody to prevent and treat influenza, into clinical development.

View Full Article in:

Mass High Tech (Boston) · Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT